🎯 Drug Targets

Browse 2 drug targets with druggability analysis, composite scores, and clinical context

2
Targets
0
High Druggability
0.66
Avg Score
15
Target Classes
Druggability Distribution
High: 0Medium: 2Low: 0Unknown: 0
Avg druggability score: 0.545
Clinical Pipeline
Approved: 2Phase III: 0Phase II: 0Phase I: 0Preclinical: 0
Total compounds: 6 · Approved: 5
Filtered by: class=ion_channel, druggability=Medium — 2 results
KCNK2 Potassium two pore domain channel subfamily K memb Phase 4
Ion Channel Medium Druggability
Score
0.73
Drug.
0.58
Safety
0.50
Drugs
5
Hyps
2
Papers
55
KCNK2 encodes a two-pore domain potassium channel (TREK-1) that regulates neuronal excitability, membrane potential, and cellular responsiveness to mechanical and chemical stimuli in the central nervous system. In neurodegeneration, TREK-1 modulation can influence neuronal survival, mitochondrial function, and potentially mitigate oxidative stress and excitotoxicity through precise potassium conductance regulation.
HCN1 Hyperpolarization-activated cyclic nucleotide-gate Phase 4
Ion Channel Medium Druggability
Score
0.59
Drug.
0.51
Safety
0.60
Drugs
1
Hyps
1
Papers
31
HCN1 encodes a hyperpolarization-activated cyclic nucleotide-gated channel critical for neuronal pacemaking and synaptic integration, with dysregulation linked to hyperexcitability disorders and potential neurodegeneration mechanisms. Specifically, HCN1 channel dysfunction can alter neuronal excitability, synaptic plasticity, and potentially contribute to neuronal death or dysfunction in conditions like epilepsy and neurodegenerative diseases.